bioAffinity Technologies Inc BIAF
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
bioAffinity Technologies Promotes Veteran Awareness and Access to Its Noninvasive CyPath® Lung Cancer Test Through Distribution Partnership with Veteran-Owned AvMEDICAL
-
bioAffinity Technologies to Present Positive Clinical and Veteran-Focused Data on CyPath® Lung at NAVREF 2026 Annual Conference
-
bioAffinity Technologies Announces Grant of Hong Kong Patent for Company's CyPath® Lung Noninvasive Lung Cancer Diagnostic
-
bioAffinity Technologies Regains Compliance with Nasdaq Listing Requirements
-
bioAffinity Technologies to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
-
bioAffinity Technologies Advances CyPath® Lung for Surveillance of Lung Cancer Survivors
-
bioAffinity Technologies Announces 1-for-15 Reverse Stock Split Effective at the Open of Trading on August 24, 2026
-
bioAffinity Technologies and AvMEDICAL Announce Nationwide Federal Healthcare Distribution Agreement for CyPath® Lung
Trading Information
- Previous Close Price
- $6.15
- Day Range
- $5.90–6.24
- 52-Week Range
- $4.56–80.70
- Bid/Ask
- $6.00 / $6.19
- Shares Outstanding
- 1.17M
- Market Cap
- $3.64M
- Volume/Avg
- 154,642 / 3M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.26
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
bioAffinity Technologies Inc develops noninvasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis informed by machine learning, a form of artificial intelligence (AI). Its first commercial diagnostic test, CyPath Lung, identifies and analyzes cell populations using flow cytometry, including cancer and cancer-related cells, that indicate a malignancy in the lung. It is developing its flow cytometry platform to address the need to identify patients who can benefit from new and emerging therapies for asthma and chronic obstructive pulmonary disease with noninvasive precision diagnostic tests. The company is organized in two operating segments, Diagnostic Research and Development and Laboratory Services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 57
- Website
- https://www.bioaffinitytech.com
Valuation
|
Metric
|
BIAF
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 0.73 |
Price/Sales | 0.26 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
BIAF
|
|---|---|
Quick Ratio | 1.24 |
Current Ratio | 1.44 |
Interest Coverage | −338.30 |
Quick Ratio
BIAF
Profitability
|
Metric
|
BIAF
|
|---|---|
Return on Assets (Normalized) | −143.36% |
Return on Equity (Normalized) | −285.88% |
Return on Invested Capital (Normalized) | −228.88% |
Return on Assets
BIAF
Diagnostics & Research Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Thermo Fisher Scientific Inc
TMO
| LOCK|!j!nb>! | LOCK|TX | $242B | |||
| Danaher Corp
DHR
| LOCK|&l?V<VF& | LOCK|jF$ | $150B | |||
| Agilent Technologies Inc
A
| LOCK|^Dp$?X< | LOCK|ZTR | $47B | |||
| IQVIA Holdings Inc
IQV
| LOCK|&?<CM% | LOCK|>^#@z | $43B | |||
| Waters Corp
WAT
| LOCK|$j%mw< | LOCK|BJN | $42B | |||
| Illumina Inc
ILMN
| LOCK|N&?wPr> | LOCK|wdW# | $41B | |||
| IDEXX Laboratories Inc
IDXX
| LOCK|%k&qLFM | LOCK|kfQ | $41B | |||
| Mettler-Toledo International Inc
MTD
| LOCK|J@$<%bJ | LOCK|KfQ$F | $30B | |||
| Quest Diagnostics Inc
DGX
| LOCK|Dcwp<t | LOCK|J&#XG | $26B | |||
| Labcorp Holdings Inc
LH
| LOCK|^x^$sh@# | LOCK|mq<& | $25B |
United States